Biomarker Testing In Upper GI Cancers - Catherine Streutker
Wed, 02 Dec 2020


Since the development of HER2 testing for upper GI cancers, there has been progress in targeted therapies for these cancers. The presentation will review Gastric HER2 testing with respect to difficult cases, and FISH and DISH evaluation. New molecular classification of gastric cancers and biomarkers for upper GI cancers will be reviewed.

At the end of the meeting participants will be able to:

  • Manage difficult gastric HER2 cases
  • Understand the new/upcoming biomarkers in upper GI cancers

Target Audience: Pathologists, Residents

CanMEDS Roles: 

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association of Pathologists. You may claim a maximum of 1.0 hour (credits are automatically calculated).

Co-Developed with Roche
Co-development is defined by the Royal College as the process by which two or more organizations — at least one of which must be a physician organization — prospectively collaborate to develop and implement an accredited educational activity, learning resource or tool.

The physician organization (CAP-ACP) has ultimate authority over all decisions and is accountable to ensure that the administrative, educational and ethical accreditation standards for group learning activities are met.

This webinar was co-developed with Roche & CAP-ACP and was planned to achieve scientific integrity, objectivity and balance.

- last updated September 2020 -